Clinical Trial Update: A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic, pharmacodynamic, and safety study of rabeprazole in newborn infants with gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Rabeprazole (rabeprazole)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Gastroesophageal Reflux | Phase 1 | Status: COMPLETED